Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Animals (Basel) ; 14(4)2024 Feb 14.
Article in English | MEDLINE | ID: mdl-38396585

ABSTRACT

A novel combination of Butyric and Valeric acid glycerol esters with oregano oil in a dry powder form was evaluated for performance improvements in broilers. The dosing regimen (500 g/Ton feed in starter and grower; 250 g/Ton in finisher feed) was considered low compared to conventional practices using non-esterified Butyric and Valeric short-chain fatty acids (SCFA). Six trials were conducted at various trial facilities in Italy, United Kingdom, Spain, and Poland. Supplemented broilers weighed significantly more than the control birds at 28 days of age (+3.4%; 1459 g vs. 1412 g; p = 0.0006) and at 42 days of age (+2.5%; 2834 g vs. 2763 g; p = 0.0030). Supplementation significantly reduced mortality from 1.9% to 0.8% during the finisher phase (from 29 to 42 days of age); however, average mortality was 3.2% for the whole 42-day growth period and was not affected. Further, supplemented broilers grew more (66.4 vs. 64.5 g/day; p = 0.0005), ate more feed (104.7 vs. 103.1 g/day; p = 0.0473), converted feed significantly more efficiently (1.58 vs. 1.60; p = 0.0072), leading to better EPEF value (410 vs. 389; p = 0.0006) than the control broilers. Meta-analysed trial performance data for novel SCFA formulations such as these are not commonly available, and serve to facilitate efficacy determination from an end-user perspective. The use of short- and medium-chain fatty acid esters in optimal low-dose combinations to reliably augment gut health and performance appears promising in commercial broiler production, and may lead to further improvements in industry practices and reduced antibiotic use.

2.
J Vet Diagn Invest ; 24(3): 601-3, 2012 May.
Article in English | MEDLINE | ID: mdl-22529134

ABSTRACT

In September 2010, an outbreak of type A botulism involved 4 horses in northern California that were fed grass clippings obtained from a nearby park. All 4 animals developed a progressive flaccid paralysis syndrome clinically consistent with exposure to preformed Clostridium botulinum neurotoxin (BoNT). Within 48 hr of consuming the grass clippings, all 4 horses showed marked cervical weakness (inability to raise their heads to a normal position) and died or were euthanized within 96 hr. One horse was submitted for diagnostic examination and subsequent necropsy. At necropsy, extensive edema was observed in areas of the nuchal ligament and inguinal fascia. A sample of the grass clippings tested positive for preformed BoNT type A by the mouse bioassay test. Emphasis should be placed on early case recognition, rapid initiation of treatment with the trivalent antitoxin product, and preventing exposure to BoNT in spoiled forages.


Subject(s)
Botulinum Toxins, Type A/metabolism , Botulism/veterinary , Clostridium botulinum/isolation & purification , Disease Outbreaks/veterinary , Horse Diseases/microbiology , Animals , Biological Assay , Botulinum Toxins, Type A/toxicity , Botulism/epidemiology , Botulism/metabolism , Botulism/microbiology , California/epidemiology , Clostridium botulinum/classification , Clostridium botulinum/metabolism , Fatal Outcome , Female , Horse Diseases/epidemiology , Horse Diseases/metabolism , Horses , Mice
3.
Cutan Ocul Toxicol ; 28(2): 78-82, 2009.
Article in English | MEDLINE | ID: mdl-19514931

ABSTRACT

The dermal absorption potential of a nanocrystalline magnesium oxide (MgO) and titanium dioxide (TiO(2)) mixture in dermatomed human skin was assessed in vitro using Bronaugh-type flow-through diffusion cells. Nanocrystalline material was applied to the skin surface at a dose rate of 50 mg/cm(2) as a dry powder, as a water suspension, and as a water/surfactant (sodium lauryl sulfate) suspension, for 8 hours. Dermal absorption of nanocrystalline MgO and TiO(2) through human skin with intact, functional stratum corneum was not detectable under the conditions of this experiment.


Subject(s)
Magnesium Oxide/pharmacokinetics , Nanoparticles , Skin Absorption , Skin/drug effects , Titanium/pharmacokinetics , Administration, Topical , Adult , Diffusion Chambers, Culture , Humans , In Vitro Techniques , Magnesium Oxide/administration & dosage , Magnesium Oxide/blood , Magnesium Oxide/chemistry , Magnesium Oxide/toxicity , Microscopy, Electron, Transmission , Models, Biological , Skin/metabolism , Skin/ultrastructure , Titanium/administration & dosage , Titanium/blood , Titanium/chemistry , Titanium/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...